

Review

Significance of diabetic kidney disease biomarkers in predicting metabolic-associated fatty liver disease

Jaehyun Bae ¹ and Byung-Wan Lee ^{2,*}

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Republic of Korea; baejh0419@gmail.com

² Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; bwanlee@yuhs.ac

* Correspondence: bwanlee@yuhs.ac

Abstract: Metabolic-associated fatty liver disease (MAFLD) and diabetic kidney disease (DKD) share various pathophysiological factors, and epidemiological evidence suggests that these two diseases are associated. Albuminuria and the estimated glomerular filtration rate, which are conventional biomarkers of DKD, are reportedly associated with the risk or severity of MAFLD. Recently, novel DKD biomarkers reflecting renal tubular injury have been introduced to complement conventional DKD markers. In this article, we looked at previous studies that showed an association between MAFLD and DKD and also reviewed the significance of DKD biomarkers as predictive risk factors for MAFLD.

Keywords: diabetic kidney disease; metabolic-associated fatty liver disease; biomarker

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is a liver condition that ranges from steatosis to steatohepatitis or fibrosis in the absence of excessive alcohol consumption [1]. The global prevalence of this disease is approximately 30% and increasing [2], and it is currently the most common chronic liver disease worldwide. In patients with type 2 diabetes (T2D), the prevalence of NAFLD is higher than that in the general population and is estimated to be 50–75% [3,4]. Recently, metabolic-associated fatty liver disease (MAFLD) was suggested to more accurately reflect the pathogenesis of chronic liver disease [5].

Chronic kidney disease (CKD) is defined as a sustained reduction in the estimated glomerular filtration rate (eGFR) or evidence of structural or functional abnormalities in the kidney [6]. It is characterized by proteinuria, low eGFR, or both, and its global prevalence is estimated to be >10%, making it one of the leading causes of mortality worldwide [7,8]. Diabetic kidney disease (DKD) is the leading cause of CKD and develops in approximately 40% of patients with T2D [9].

The liver and kidneys are critical for maintaining homeostasis. Because they are affected by systemic changes and have significant effects on other organs, it can be expected that they can influence each other. MAFLD and DKD share many metabolic risk factors and pro-inflammatory pathways [10]. Recently, several studies have reported the association between MAFLD and CKD or DKD [11–17].

In this article, we review the results of previous studies on the association between MAFLD and DKD, the possible mechanisms linking these diseases, and the association between the biomarkers of DKD and MAFLD.

2. Overlap between MAFLD and DKD

2.1. Epidemiologic perspective

As the prevalence of MAFLD and CKD increases, interest in and research on these diseases with increased prevalence has also increased. Accordingly, studies investigating the association between MAFLD and CKD have been actively conducted. Among them, the majority of studies have investigated whether MAFLD affects the occurrence of CKD. In 2014, a meta-analysis of 20 studies (11 cross-sectional and 9 longitudinal) reported that the presence and severity of MAFLD were associated with the risk and severity of CKD [11]. Several years later, a meta-analysis that included

nine longitudinal studies reported that MAFLD was associated with an approximately 40% increase in the risk of incident CKD [12]. These analyses defined CKD as an eGFR < 60 mL/min/1.73 m² and/or proteinuria regardless of a cause such as DKD.

To date, no meta-analysis has reported the association between MAFLD and DKD, which is the leading cause of CKD. Several longitudinal studies have been conducted on this topic. In 2008, Italian researchers reported a higher prevalence of DKD in T2D patients with MAFLD in a large cohort study using a cross-sectional design [13]. Shortly thereafter, they published a longitudinal analysis following up 1760 patients with T2D and normal or near-normal kidney function and without overt proteinuria to find the occurrence of DKD, defined as overt proteinuria and/or eGFR < 60 mL/min/1.73 m² for 6.5 years [14]. As a result, MAFLD, diagnosed by liver ultrasound, was associated with an increased incidence of DKD [hazard ratio (HR) 1.69; 95% confidence interval (CI) 1.3 to 2.6; P < 0.001]. Consistent results have also been reported in another study that recruited an Asian population [15]. In that study, the cumulative incidence of DKD was higher in patients with T2D and MAFLD, and the liver fat content showed a positive relationship with albuminuria and a negative relationship with eGFR. In 2022, Korean researchers demonstrated the relationship between liver fibrosis and DKD [16]. Initially, they failed to show the differential risk of incident DKD between the MAFLD and non-MAFLD groups; however, among the T2D patients with MAFLD, advanced liver fibrosis was significantly associated with DKD (HR 1.75; 95% CI 1.15 to 2.66; P=0.009). Similar results were reported by Chinese researchers [17]. They showed an association between liver fibrosis and DKD incidence and progression in older patients with T2D through both cross-sectional and longitudinal designs. In the case of type 1 diabetes (T1D), another study reported an association between MAFLD and DKD [18]. The result was similar to that of patients with T2D (HR 2.85; 95% CI 1.59 to 5.10; P<0.001). In addition to the studies mentioned above, several longitudinal and cross-sectional studies have reported a significant association between MAFLD and DKD [19-23]. **Table 1** summarizes the previous studies that have investigated the association between MAFLD and DKD.

Table 1. Previous studies reporting the association between DKD biomarkers and MAFLD.

Design	Patients	Independent variable	Dependent variable	Main finding
Cross-sectional [13]	2103 T2D patients	MAFLD by ultrasound	UACR>30mg/g and/or eGFR< 60 mL/min/1.73m ²	OR 1.87; 95% CI 1.3 to 4.1
Cohort [14]	1760 T2D patients	MAFLD by ultrasound	UACR>30mg/g and/or eGFR< 60 mL/min/1.73m ²	HR 1.69; 95% CI 1.3 to 2.6
Cohort [15]	169 T2D matched pairs	MAFLD severity by ultrasound	Incidence of albuminuria (24-hour urine albumin > 30mg)	Increased more in the severe MAFLD group
			Change in eGFR	Decreased more in the severe MAFLD group
Cohort [16]	1729 patients with T2D and MAFLD	FIB-4 index ≥ 2.67	eGFR< 60 mL/min/1.73m ²	HR 1.75; 95% CI 1.15 to 2.66
Cohort [17]	1734 T2D patients	FIB-4 index 1.30-3.25	eGFR< 60 mL/min/1.73m ²	HR 1.27; 95% CI 1.06 to 1.51
		FIB-4 index > 3.25		HR 2.52 95% CI 1.97 to 3.21
Cross-sectional [17]	3445 T2D patients	FIB-4 index 1.30-3.25	eGFR< 60 mL/min/1.73m ²	OR 1.52; 95% CI 1.12 to 2.07
		FIB-4 index > 3.25		OR 3.62; 95% CI 2.26 to 5.80
Cohort [22]	3627 T2D patients	MAFLD by ultrasound	eGFR< 60 mL/min/1.73m ² or ≥2 proteinuria by dipstick	HR 1.30; 95 % CI 1.11 to 1.53
Cohort [23]	2057 T2D patients	Liver steatosis (HSI, ZJU)	Albuminuria progression*	HR 1.02; 95% CI 1.00 to 1.03
		Liver fibrosis (BARD)	≥ 40% eGFR decline	HR 1.12; 95% CI 1.01 to 1.24
Cross-sectional [24]	1763 T2D patients	Liver fibrosis by transient elastography	Incidence of albuminuria (UACR ≥ 3.5 mg/mmol in women and ≥ 2.5 mg/mmol in men)	OR 1.52; 95% CI 1.02 to 2.28
		Fatty liver index (FLI)	UACR > 30mg/g	OR 3.49; 95% CI 2.05 to 5.94

Cross-sectional [25]	2770 T2D patients		eGFR< 60 mL/min/1.73m ²	OR 1.77; 95% CI 1.15 to 2.72
Cross-sectional [26]	100 T2D patients	UACR ≥ 30mg/g	MAFLD by transient elastography	OR 1.88; 95% CI 1.31 to 2.71
Cross-sectional [21]	1168 T2D patients	UACR ≥ 300mg/g	MAFLD by ultrasound	OR 2.34; 95% CI 1.20 to 4.56 (vs. UACR<30mg/g)
Cross-sectional [27]	2689 T2D patients	eGFR	Hepatic fibrosis by NFS (>0.676)	OR 0.26; 95% CI 0.09 to 0.74
Cross-sectional [28]	1108 T2D patients	UACR ≥ 30 mg/g	Hepatic steatosis by NLFS	OR 1.56; 95% CI 1.01 to 2.40
		UPCR ≥ 150 mg/g	Hepatic fibrosis by NFS	OR 1.55; 95% CI 1.03 to 2.33
Cross-sectional [29]	300 T2D patients	Urinary NAG	Hepatic fibrosis by transient elastography	F2: OR 1.99; 95% CI 1.04 to 3.82
				F3,4: OR 2.4; 95% CI 1.52 to 3.80

*Defined as an increase in the albuminuria stage from normoalbuminuria to microalbuminuria or from microalbuminuria to macroalbuminuria.

Abbreviations; T2D, type 2 diabetes; MAFLD, metabolic-associated fatty liver disease; UACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval; HR, hazard ratio; FIB-4, fibrosis-4 index; HSI, hepatic steatosis index; ZJU, Zhejiang University index; NLFS, NAFLD liver fat score; NFS, NAFLD fibrosis score; UPCR, urine protein-to-creatinine ratio; NAG, N-acetyl-beta-D-glucosaminidase

Although considerable evidence has been accumulated, a clear causal relationship between MAFLD and DKD has not yet been identified. Most previous studies adjusted for important risk factors, such as age, sex, body mass index (BMI), glycated hemoglobin (HbA1c), and comorbidities; however, it might be insufficient to adjust for factors shared by MAFLD and DKD, including insulin resistance and abdominal obesity. In addition, studies on the histological findings of MAFLD and DKD are scarce. Studies on changes in DKD according to the progression or improvement of MAFLD, and vice versa, are also lacking. Large-scale studies that address these limitations are required to clarify the association between MAFLD and DKD.

2.2. Pathophysiological mechanisms linking MAFLD and DKD

Based on the epidemiological evidence described above, MAFLD and DKD are considered to be closely related. Although the precise mechanisms linking MAFLD and DKD are not fully understood, several potential factors and mechanisms may link them.

First, as can be inferred from the names, MAFLD and DKD share broad areas of metabolic dysfunction, such as obesity, insulin resistance, hypertension, dyslipidemia, and diabetes [30]. Insulin resistance is one of the most important pathogenic mechanisms underlying MAFLD and T2D. Insulin resistance, which is also widely known as a fundamental pathological factor in metabolic syndrome, increases lipolysis in adipose tissue, thereby increasing the plasma concentration of free fatty acids [31-33]. This induces an excessive accumulation of hepatic triglycerides, resulting in the development and progression of MAFLD. Insulin resistance also results in compensatory hyperinsulinemia, which increases hepatic fatty acid uptake and inhibits β-oxidation, thereby leading to *de novo* lipogenesis and aggravation of MAFLD. Lipid overload in the liver contributes to the formation of lipotoxic lipids, which leads to the activation of inflammatory responses, mitochondrial dysfunction, and oxidative stress [33]. Progression to hepatic inflammation, that is, the metabolic-associated steatohepatitis state, is not limited to the inflammatory response in the liver but also increases systemic inflammatory responses [34]. Delivery of pro-inflammatory mediators to the kidneys via systemic circulation may act as initiating or aggravating factors for kidney diseases. Inflammatory processes play an important role in the initiation and development of DKD [35,36]. In addition, an increase in oxidative stress leads to a reduction in the level of antioxidant factors in the kidney, such as the Klotho protein [37]. Similar to the other mechanisms discussed below, insulin resistance, MAFLD, and DKD interact with each other, making it difficult to determine the precedence relationship. Insulin resistance is an important pathogenic mechanism of MAFLD that can affect the kidney through various path-

ways, such as systemic inflammation and oxidative stress. On the other hand, insulin resistance can directly affect kidneys via its pro-inflammatory features and hemodynamic alteration, and vice versa; insulin resistance is known to be a common and very early alteration in CKD, which includes the concept of DKD [38].

Second, expansion and inflammation of the adipose tissue is another common metabolic dysfunction shared by MAFLD and DKD [10]. This encompasses unhealthy diet, obesity, and insulin resistance. Expanded or inflamed adipose tissue releases large amounts of fatty acids into the systemic circulation [10,39,40], which are transported to the liver and cause MAFLD. Inflamed adipose tissue also secretes various pro-inflammatory cytokines such as tumor necrosis factor- α , interleukin-6, resistin, and monocyte chemoattractant protein-1 and increases oxidative stress. MAFLD and systemic inflammation affect the kidneys. Furthermore, renal fat accumulation increases in obese individuals, which may result in local adverse reactions [41,42]. Adiponectin is a representative adipokine that is dysregulated [10,43]. The mechanisms by which adiponectin improves insulin resistance and inhibits reactive oxygen species (ROS) through adenosine monophosphate-activated protein kinase activation have a protective effect against MAFLD and podocyte injury [44]. In contrast, fetuin-A, a hepatokine, induces insulin resistance and suppresses adiponectin production in the adipose tissue [45,46]. The interplay between pro-insulin-resistant fetuin-A and pro-insulin-sensitive adiponectin is considered a common pathogenic mechanism in MAFLD and DKD [10,43,44,47]. Recently, perturbation of the gut microbiota has emerged as a common pathophysiology in MAFLD and DKD [10,30,43,48,49]. Genetic, environmental, and nutritional factors can influence the composition of gut bacteria [50]. In particular, an unhealthy diet adversely alters the intestinal flora. This change, the so-called intestinal dysbiosis, causes the production of gut-derived toxins and promotes their absorption by damaging the intestinal barrier integrity [43]. Increased absorption and accumulation of toxins lead to systemic inflammation, ectopic fat deposition, and insulin resistance. Renal excretion of the toxins and their metabolites can also damage the kidneys [30].

Hyperglycemia can adversely affect both the liver and kidneys in patients with T2D. High concentrations of glucose in the plasma are delivered to the liver and used for *de novo* lipogenesis [51]. Hyperglycemia induces glomerular hyperfiltration, which initiates and propagates kidney damage in T2D [9,36]. Alteration of glucose metabolism in the kidney also promotes inflammatory responses and fibrotic changes, wherein advanced glycation end products and ROS are the major mediators [36]. Furthermore, in T2D, tubular glucose reabsorption and renal gluconeogenesis are usually increased [52,53]. These changes demand an increased consumption of oxygen, leading to proximal tubule damage, which increases vulnerability to hypoxia [54-57].

Activation of the renin-angiotensin system (RAS), particularly angiotensin II production, plays an important role in the pathogenesis of MAFLD and CKD [43,58]. In the liver, RAS activation promotes *de novo* lipogenesis, insulin resistance, and production of pro-inflammatory cytokines [59,60], thereby leading to the development of MAFLD. In the kidney, RAS activation induces renal fat accumulation, inflammatory processes, and vessel constriction, which cause and worsen CKD or DKD [60,61]. In contrast, the progression of DKD also activates RAS; decreased renal blood flow and glomerular filtration rate in the progressive stage of DKD promote renin secretion, thereby activating RAS [62].

Finally, MAFLD and DKD share genetic susceptibilities [30,49]. A representative example is the genetic polymorphism in *PNPLA3* [63], which encodes patatin-like phospholipase domain-containing protein 3 (PNPLA3) and is known to have lipase activity [64]. The *PNPLA3* gene is expressed in the liver and kidneys. *PNPLA3* rs 738409 polymorphism has been associated with poor renal outcomes and MAFLD severity [63,65-67]. Other genetic abnormalities, such as transmembrane 6 superfamily member 2 (*TM6SF2*) and glucokinase regulator (*GCKR*) polymorphisms, have also been reported to be associated with the risk of both MAFLD and CKD [65,68-70]. A schematic diagram summarizing the pathophysiological mechanisms linking MAFLD and DKD is shown in **Figure 1**.




Figure 1. Schematic diagram of common pathogenic mechanisms between MAFLD and DKD.

3. Biomarkers of DKD and MAFLD

As described in the introduction section, DKD is the leading cause of CKD and one of the most important micro-vascular complications of T2D [71]. In patients with diabetes, screening for DKD is based on albuminuria and eGFR [72]. Therefore, albuminuria and the eGFR are the representative biomarkers of DKD. We review the association between these conventional DKD biomarkers and MAFLD and then describe the association between tubular markers, introduced as complementary biomarkers for DKD and MAFLD.

3.1. Conventional glomerular biomarkers: albuminuria and eGFR

Albuminuria is usually assessed by the random spot urinary albumin-to-creatinine ratio (UACR) [72]. Normal albuminuria is defined as a UACR < 30 mg/g. Diabetic patients with UACR ≥ 30 mg/g in two of three samples collected within 6 months are considered to have DKD. In patients with DKD, most urinary albumin is excreted through trans glomerular passage [73]. The major mechanism of albuminuria is the impairment of selective permeability of the glomerulus due to glomerular endothelial dysfunction [74]. Therefore, albuminuria primarily reflects glomerular damage.

eGFR is calculated by validated formulas, using serum creatinine, and other variables such as age, sex, and race [75]. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is currently the preferred formulation. In the patient’s laboratory reports, eGFR is usually reported along with the creatinine level, and when it is persistently reduced to < 60 mL/min/1.73 m², it is generally interpreted as progressing to a significantly pathological stage [72]. Based on the generally accepted natural course of DKD [76], eGFR decline is believed to occur later than albuminuria.

Considering the guidelines for DKD screening, researchers usually defined DKD as a UACR ≥ 30 mg/g and/or eGFR < 60 mL/min/1.73 m² when they studied the association between DKD and MAFLD, but some studies included total proteinuria or changes in UACR and/or eGFR as variables. In the two meta-analyses introduced in section 2.1 that showed an association between MAFLD and CKD, CKD was defined as the status covering persistent eGFR < 60 mL/min/1.73 m², albuminuria, and proteinuria on morning urine dipstick. As described in the previous section, no meta-

analyses have investigated the association between MAFLD and DKD. However, in 2018, a meta-analysis that summarized the data and estimated the risk of albuminuria among patients with NAFLD showed the results of a subgroup analysis including only patients with diabetes [77]. The subgroup analysis demonstrated no significant association between albuminuria and NAFLD among patients with diabetes [pooled odds ratio (OR) 1.28; 95% CI 0.94 to 1.75], but a significantly increased risk of albuminuria among patients with NAFLD without diabetes (pooled OR 2.25, 95% CI 1.65 to 3.06). However, since then, several studies analyzing a large number of patients with longitudinal or cross-sectional designs have been conducted [16,17,21,25], and most of them have reported a significant association between MAFLD and DKD.

Most of the studies that investigated the association between MAFLD and DKD were designed to evaluate whether MAFLD increased the risk of DKD; the independent variable was MAFLD, assessed by ultrasound, noninvasive indices, or transient elastography (TE), whereas the dependent variable was DKD assessed by albuminuria, proteinuria, or eGFR (**Table 1**). Studies on whether DKD affected the occurrence or severity of MAFLD and whether DKD biomarkers were related to MAFLD are limited. Several cross-sectional studies have reported that DKD biomarkers can predict the prevalence and severity of MAFLD.

In 2020, Chinese researchers conducted a study that recruited 2689 patients with MAFLD and T2D and explored whether a lower eGFR was associated with an increased probability of liver fibrosis [27]. During the inclusion process, MAFLD was determined using ultrasonography. The NAFLD fibrosis score (NFS) was used to evaluate the risk of liver fibrosis. In that study, a negative correlation was found between eGFR and NFS, and the prevalence of liver fibrosis was increased as eGFR quartiles decreased, after adjustment for conventional risk factors (Q4: reference; Q3: OR 1.49; 95% CI 0.82 to 2.71; Q2: OR 1.88; 95% CI 0.97 to 3.67; Q1: OR 2.70; 95% CI 1.36 to 5.37; P for trend = 0.002). In the same year, Korean researchers reported an association between albuminuria and MAFLD indices [28]. In that study that enrolled 1108 patients with T2D, the UACR was positively correlated with the NAFLD liver fat score (NLFS), fibrosis-4 index (FIB-4), and NFS. In the logistic regression analysis, albuminuria defined as a UACR ≥ 30 mg/g was significantly associated with hepatic steatosis according to NLFS and fibrosis according to NFS, after adjustment for age, sex, and BMI. After further adjustment for HbA1c, homeostasis model assessment of insulin resistance (HOMA-IR), and T2D duration, the association between albuminuria and NLFS remained statistically significant. This study was strengthened by a study published the following year that used TE as an investigative tool for MAFLD; albuminuria was associated with significant steatosis, defined as a controlled attenuation parameter > 302 db/m [26]. In 2022, another research group reported that when patients with T2D were divided into three groups based on a UACR of 30 mg/g and 300 mg/g, the prevalence of MAFLD diagnosed by ultrasound was higher in the group with more severe albuminuria [21].

As described thus far, MAFLD can be considered to be correlated with conventional DKD biomarkers, albuminuria, and eGFR. In addition, several cross-sectional studies have reported that conventional DKD biomarkers can predict the risk of MAFLD. As reviewed in section 2.2, DKD status can affect the liver. Furthermore, albuminuria is closely related to insulin resistance [78,79] and a decreased eGFR generally reflects a later stage of DKD than albuminuria. Considering these points, these results are convincing. Large-scale longitudinal studies are required to clarify the association between conventional DKD biomarkers and MAFLD.

3.2. Biomarkers for renal tubular injury

Various factors, such as insulin resistance, hyperglycemia, oxidative stress, and inflammatory processes, play complex roles in the pathogenesis of DKD (**figure 1**). Structural changes caused by DKD can also manifest as various alterations in the kidneys, including thickening of the glomerular basement membrane (GBM), mesangial expansion, glomerulosclerosis, and tubular fibrosis or atrophy, etc. [9,80-82]. Conventionally, investigations into DKD have focused on glomerular alterations; thickening of the GBM is known to be the earliest structural change in DKD [80], and albuminuria, the most commonly used early DKD biomarker, mainly reflects glomerular damage. However, cases of DKD without significant glomerular alterations have been reported [83,84] a considerable number of patients with diabetes develop renal impairment without preceding albuminuria.

To overcome this limitation, alterations in renal tubules have gained attention as another important aspect of DKD. Several studies have shown the potential for preceding tubulopathy to cause glomerulopathy in diabetes [87,88], suggesting that detecting tubular damage might be faster than detecting glomerular damage as assessed by albuminuria in identifying DKD in certain groups of patients with T2D. As described in section 2.2, hypoxic damage to the proximal tubules can be induced in T2D [52-56]. RAS activation causes tubular and glomerular damage [85]. Furthermore, under

diabetic conditions, the activities of growth factors, such as transforming growth factor- β , epidermal growth factor, and insulin-like growth factor-1 in renal tubules are increased [82,86], and tubular inflammation and tubulointerstitial fibrosis are induced.

Based on these mechanistic bases and clinical necessity, several biomarkers for tubular injuries, such as N-acetyl-beta-D-glycosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty acid-binding protein (L-FABP), and kidney injury molecule-1 (KIM-1) have been introduced as complementary biomarkers for DKD [57]. NAG is a lysosomal enzyme found in the proximal tubule epithelial cells, and urinary NAG is highly sensitive to tubular injury [87,88]. NAG not only reflects DKD status [87-89] but is also closely related to various glycemic parameters [90,91]. NGAL is a small protein released from neutrophils and epithelial cells in the renal tubules, lungs, prostate, and digestive tract [92,93]. Owing to its small size, most of the NGAL is filtered through the glomerulus and reabsorbed in the renal tubule [94]. Therefore, in tubular injury, urinary NGAL levels increase. Similar to NAG, urinary NGAL levels are associated with DKD and glycemic control [87,95]. Blood NGAL levels have also been associated with DKD [93,96]. L-FABP is another small protein that is expressed in the proximal tubules and liver [92]. It reflects tubular stress or hypoxia [97] and has been reported to be associated with early-stage DKD and its progression [98-101]. KIM-1 is a transmembrane glycoprotein that is expressed when the proximal tubule is damaged or dedifferentiated after an injury [102]. Its presence in the urine has been reported to be specific for renal tubular damage [102,103], and the association between DKD and urinary KIM-1 has also been reported in several previous studies [95,104]. In addition to these biomarkers, other tubular markers, including retinol-binding protein, alpha-1 microglobulin, and beta-2 microglobulin, have also been reported, and their association with DKD has been presented [57,92]. Because it is difficult to measure each biomarker individually, and no tubular marker has been recognized as a standard biomarker for DKD screening, non-albumin proteinuria (NAP), which can be calculated by subtracting urinary albumin from total protein, has been introduced as an accessible tubular marker that includes a wide range of biomarkers for tubular injury [57]. To summarize the clinical relevance of renal tubular biomarkers, no biomarker of choice represents the standard for detecting renal tubular injuries, such as albuminuria and e-GFR, for detecting glomerular injury and function, respectively.

These tubular markers have received attention relatively recently. Therefore, studies investigating the association between these markers and MAFLD are limited. In the study that showed the association between albuminuria and hepatic steatosis which was introduced in section 3.1 [28], the researchers also investigated the association between total proteinuria and MAFLD indices. In that study, proteinuria, including urinary albumin and non-albumin proteins, which reflect both glomerular and tubular injury, was defined as spot urinary protein-to-creatinine ratio (UPCR) ≥ 150 mg/g. Proteinuria was associated with liver fibrosis according to the NFS and remained statistically significant even in the final model adjusted for age, sex, BMI, HbA1c, HOMA-IR, duration of T2D, hypertension, alanine aminotransferase level, and total cholesterol level. It can be interpreted that total proteinuria is associated with liver fibrosis, whereas albuminuria is associated with hepatic steatosis. In that study, patients with T2D were divided into three groups based on the UACR and UPCR: non-proteinuria, isolated NAP, and albuminuria groups. Interestingly, patients with isolated NAP showed a significantly increased NFS, comparable to that of the albuminuria group, whereas there was no difference in NLFS. A similar trend was reported in a study using urinary NAG as a biomarker [29]. In patients with T2D, NAG was associated with greater OR for the risk of higher liver fibrosis stage, assessed by TE (F0,1: reference; F2: OR 1.99; 95% CI 1.04 to 3.82; F3,4: OR 2.40; 95% CI 1.52 to 3.80), whereas there was no significant association with the risk of steatosis stage. Taken together, these results suggest that biomarkers of tubular injury may show significant associations with MAFLD, particularly with liver fibrosis.

To date, no studies have used other tubular markers as DKD biomarkers to investigate their association with MAFLD. Because the tubular injury is an important phenotype of DKD and is thought to affect the liver, further studies on the association between these tubular markers and MAFLD are warranted. NGAL and L-FABP have been reported to be related to types of liver injury or liver diseases other than MAFLD [105-108]. These factors are likely to be associated with MAFLD.

4. Conclusions

MAFLD and DKD share several epidemiologic and pathophysiologic factors and are associated with each other. Accumulating evidence suggests that DKD biomarkers are associated with MAFLD and can predict its occurrence or severity. Because MAFLD is reversible in the early stages, clinicians should check for the presence or severity of MAFLD

when treating diabetic patients with DKD. Further studies on the association between tubular markers and MAFLD are required to overcome the limitations of conventional DKD markers.

Funding: This study received no external funding.

Acknowledgments: We would like to thank Editage (www.editage.co.kr) for English language editing.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Diehl, A.M.; Day, C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. *The New England journal of medicine* **2017**, *377*, 2063-2072.
2. Younossi, Z.M.; Golabi, P.; Paik, J.M.; Henry, A.; Van Dongen, C.; Henry, L. The global epidemiology of nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash): A systematic review. *Hepatology (Baltimore, Md.)* **2023**, *77*, 1335-1347.
3. Lee, Y.H.; Cho, Y.; Lee, B.W.; Park, C.Y.; Lee, D.H.; Cha, B.S.; Rhee, E.J. Nonalcoholic fatty liver disease in diabetes. Part i: Epidemiology and diagnosis. *Diabetes Metab J* **2019**, *43*, 31-45.
4. Younossi, Z.M.; Golabi, P.; de Avila, L.; Paik, J.M.; Srishord, M.; Fukui, N.; Qiu, Y.; Burns, L.; Afendy, A.; Nader, F. The global epidemiology of nafld and nash in patients with type 2 diabetes: A systematic review and meta-analysis. *Journal of hepatology* **2019**, *71*, 793-801.
5. Eslam, M.; Sanyal, A.J.; George, J. Mafld: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology* **2020**, *158*, 1999-2014.e1991.
6. James, M.T.; Hemmelgarn, B.R.; Tonelli, M. Early recognition and prevention of chronic kidney disease. *Lancet (London, England)* **2010**, *375*, 1296-1309.
7. GBD_Chronic_Kidney_Disease_Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the global burden of disease study 2017. *Lancet (London, England)* **2020**, *395*, 709-733.
8. Kovesdy, C.P. Epidemiology of chronic kidney disease: An update 2022. *Kidney international supplements* **2022**, *12*, 7-11.
9. Alicic, R.Z.; Rooney, M.T.; Tuttle, K.R. Diabetic kidney disease: Challenges, progress, and possibilities. *Clinical journal of the American Society of Nephrology : CJASN* **2017**, *12*, 2032-2045.
10. Targher, G.; Chonchol, M.B.; Byrne, C.D. Ckd and nonalcoholic fatty liver disease. *American journal of kidney diseases : the official journal of the National Kidney Foundation* **2014**, *64*, 638-652.
11. Musso, G.; Gambino, R.; Tabibian, J.H.; Ekstedt, M.; Kechagias, S.; Hamaguchi, M.; Hultcrantz, R.; Hagström, H.; Yoon, S.K.; Charatcharoenwittaya, P. *et al.* Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. *PLoS medicine* **2014**, *11*, e1001680.
12. Mantovani, A.; Zaza, G.; Byrne, C.D.; Lonardo, A.; Zoppini, G.; Bonora, E.; Targher, G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. *Metabolism: clinical and experimental* **2018**, *79*, 64-76.
13. Targher, G.; Bertolini, L.; Rodella, S.; Zoppini, G.; Lippi, G.; Day, C.; Muggeo, M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. *Diabetologia* **2008**, *51*, 444-450.
14. Targher, G.; Chonchol, M.; Bertolini, L.; Rodella, S.; Zenari, L.; Lippi, G.; Franchini, M.; Zoppini, G.; Muggeo, M. Increased risk of ckd among type 2 diabetics with nonalcoholic fatty liver disease. *Journal of the American Society of Nephrology : JASN* **2008**, *19*, 1564-1570.
15. Jia, G.; Di, F.; Wang, Q.; Shao, J.; Gao, L.; Wang, L.; Li, Q.; Li, N. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. *PloS one* **2015**, *10*, e0142808.

16. Seo, D.H.; Suh, Y.J.; Cho, Y.; Ahn, S.H.; Seo, S.; Hong, S.; Lee, Y.H.; Choi, Y.J.; Lee, E.; Kim, S.H. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. *Diabetes Metab J* **2022**, *46*, 630-639.
17. Sun, Y.; Hong, L.; Huang, Z.; Wang, L.; Xiong, Y.; Zong, S.; Zhang, R.; Liu, J.; Zang, S. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. *The Journal of clinical endocrinology and metabolism* **2022**, *107*, e3661-e3669.
18. Targher, G.; Mantovani, A.; Pichiri, I.; Mingolla, L.; Cavalieri, V.; Mantovani, W.; Pancheri, S.; Trombetta, M.; Zoppini, G.; Chonchol, M. *et al.* Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. *Diabetes care* **2014**, *37*, 1729-1736.
19. Li, Y.; Zhu, S.; Li, B.; Shao, X.; Liu, X.; Liu, A.; Wu, B.; Zhang, Y.; Wang, H.; Wang, X. *et al.* Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. *International urology and nephrology* **2014**, *46*, 1785-1791.
20. Mantovani, A.; Turino, T.; Lando, M.G.; Gjini, K.; Byrne, C.D.; Zusi, C.; Ravaioli, F.; Colecchia, A.; Maffei, C.; Salvagno, G. *et al.* Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. *Diabetes & metabolism* **2020**, *46*, 296-303.
21. Zhao, P.; Yan, J.; Pan, B.; Liu, J.; Fu, S.; Cheng, J.; Wang, L.; Jing, G.; Li, Q. Association between the risk of non-alcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease. *Diabetes, metabolic syndrome and obesity : targets and therapy* **2022**, *15*, 1141-1151.
22. Wei, S.; Song, J.; Xie, Y.; Huang, J.; Yang, J. Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. *Diabetes research and clinical practice* **2023**, *197*, 110563.
23. Moh, M.C.; Pek, S.L.T.; Sze, K.C.P.; Low, S.; Subramaniam, T.; Ang, K.; Tang, W.E.; Lee, S.B.M.; Sum, C.F.; Lim, S.C. Associations of non-invasive indices of liver steatosis and fibrosis with progressive kidney impairment in adults with type 2 diabetes. *Acta diabetologica* **2023**, doi:10.1007/s00592-023-02058-3.
24. Yeung, M.W.; Wong, G.L.; Choi, K.C.; Luk, A.O.; Kwok, R.; Shu, S.S.; Chan, A.W.; Lau, E.S.H.; Ma, R.C.W.; Chan, H.L. *et al.* Advanced liver fibrosis but not steatosis is independently associated with albuminuria in chinese patients with type 2 diabetes. *Journal of hepatology* **2017**, doi:10.1016/j.jhep.2017.09.020.
25. Ciardullo, S.; Muraca, E.; Perra, S.; Bianconi, E.; Zerbini, F.; Oltolini, A.; Cannistraci, R.; Parmeggiani, P.; Manzoni, G.; Gastaldelli, A. *et al.* Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. *BMJ open diabetes research & care* **2020**, *8*.
26. Han, E.; Kim, M.K.; Jang, B.K.; Kim, H.S. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. *Diabetes Metab J* **2021**, *45*, 698-707.
27. Wang, Y.; Yu, Y.; Wan, H.; Chen, Y.; Xia, F.; Zhang, W.; Zhang, K.; Gu, X.; Zhang, Y.; Lin, Z. *et al.* Lower egfr is associated with increased probability of liver fibrosis in chinese diabetic patients. *Diabetes/metabolism research and reviews* **2020**, *36*, e3294.
28. Han, E.; Cho, Y.; Kim, K.W.; Lee, Y.H.; Kang, E.S.; Cha, B.S.; Lee, B.W. Hepatic fibrosis is associated with total proteinuria in korean patients with type 2 diabetes. *Medicine* **2020**, *99*, e21038.
29. Kim, H.K.; Lee, M.; Lee, Y.H.; Kang, E.S.; Cha, B.S.; Lee, B.W. Renal tubular damage marker, urinary n-acetyl- β -d-glucosaminidase, as a predictive marker of hepatic fibrosis in type 2 diabetes mellitus. *Diabetes Metab J* **2022**, *46*, 104-116.
30. Truong, E.; Noureddin, M. The interplay between nonalcoholic fatty liver disease and kidney disease. *Clinics in liver disease* **2022**, *26*, 213-227.
31. Perdomo, C.M.; Frühbeck, G.; Escalada, J. Impact of nutritional changes on nonalcoholic fatty liver disease. *Nutrients* **2019**, *11*.
32. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "hits"? *Gastroenterology* **1998**, *114*, 842-845.

33. Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of nafld development and therapeutic strategies. *Nature medicine* **2018**, *24*, 908-922.
34. Targher, G.; Chonchol, M.; Miele, L.; Zoppini, G.; Pichiri, I.; Muggeo, M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Seminars in thrombosis and hemostasis* **2009**, *35*, 277-287.
35. Alicic, R.Z.; Johnson, E.J.; Tuttle, K.R. Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. *Advances in chronic kidney disease* **2018**, *25*, 181-191.
36. Tuttle, K.R.; Agarwal, R.; Alpers, C.E.; Bakris, G.L.; Brosius, F.C.; Kolkhof, P.; Uribarri, J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. *Kidney international* **2022**, *102*, 248-260.
37. Olejnik, A.; Franczak, A.; Krzywonos-Zawadzka, A.; Kałużna-Oleksy, M.; Bil-Lula, I. The biological role of klotho protein in the development of cardiovascular diseases. *BioMed research international* **2018**, *2018*, 5171945.
38. Spoto, B.; Pisano, A.; Zoccali, C. Insulin resistance in chronic kidney disease: A systematic review. *American journal of physiology. Renal physiology* **2016**, *311*, F1087-f1108.
39. Shoelson, S.E.; Herrero, L.; Naaz, A. Obesity, inflammation, and insulin resistance. *Gastroenterology* **2007**, *132*, 2169-2180.
40. Byrne, C.D. Dorothy hodgkin lecture 2012: Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: A new problem in diabetes management. *Diabetic medicine : a journal of the British Diabetic Association* **2012**, *29*, 1098-1107.
41. Deji, N.; Kume, S.; Araki, S.; Soumura, M.; Sugimoto, T.; Isshiki, K.; Chin-Kanasaki, M.; Sakaguchi, M.; Koya, D.; Haneda, M. *et al.* Structural and functional changes in the kidneys of high-fat diet-induced obese mice. *American journal of physiology. Renal physiology* **2009**, *296*, F118-126.
42. Bobulescu, I.A.; Dubree, M.; Zhang, J.; McLeroy, P.; Moe, O.W. Effect of renal lipid accumulation on proximal tubule na⁺/h⁺ exchange and ammonium secretion. *American journal of physiology. Renal physiology* **2008**, *294*, F1315-1322.
43. Sharma, N.; Sircar, A.; Anders, H.J.; Gaikwad, A.B. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: Mechanisms and therapeutic approaches. *Archives of physiology and biochemistry* **2022**, *128*, 1024-1038.
44. Ix, J.H.; Sharma, K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-a, adiponectin, and ampk. *Journal of the American Society of Nephrology : JASN* **2010**, *21*, 406-412.
45. Icer, M.A.; Yıldıran, H. Effects of nutritional status on serum fetuin-a level. *Critical reviews in food science and nutrition* **2020**, *60*, 1938-1946.
46. Hennige, A.M.; Staiger, H.; Wicke, C.; Machicao, F.; Fritsche, A.; Häring, H.U.; Stefan, N. Fetuin-a induces cytokine expression and suppresses adiponectin production. *PloS one* **2008**, *3*, e1765.
47. Ju, H.; Zhou, Z.; Sun, M.; Chen, H. Association of fetuin-a to adiponectin ratio with metabolic syndrome: A cross-sectional study. *Endocrine* **2017**, *58*, 190-193.
48. Byrne, C.D.; Targher, G. Nafld as a driver of chronic kidney disease. *Journal of hepatology* **2020**, *72*, 785-801.
49. Perdomo, C.M.; Garcia-Fernandez, N.; Escalada, J. Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: A new triumvirate? *Journal of clinical medicine* **2021**, *10*.
50. Wen, L.; Duffy, A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. *The Journal of nutrition* **2017**, *147*, 1468s-1475s.
51. Sanders, F.W.; Griffin, J.L. De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose. *Biological reviews of the Cambridge Philosophical Society* **2016**, *91*, 452-468.
52. DeFronzo, R.A.; Hompesch, M.; Kasichayanula, S.; Liu, X.; Hong, Y.; Pfister, M.; Morrow, L.A.; Leslie, B.R.; Boulton, D.W.; Ching, A. *et al.* Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. *Diabetes care* **2013**, *36*, 3169-3176.
53. Meyer, C.; Stumvoll, M.; Nadkarni, V.; Dostou, J.; Mitrakou, A.; Gerich, J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. *The Journal of clinical investigation* **1998**, *102*, 619-624.

54. Körner, A.; Eklöf, A.C.; Celsi, G.; Aperia, A. Increased renal metabolism in diabetes. Mechanism and functional implications. *Diabetes* **1994**, *43*, 629-633.
55. Zhan, M.; Usman, I.M.; Sun, L.; Kanwar, Y.S. Disruption of renal tubular mitochondrial quality control by myo-inositol oxygenase in diabetic kidney disease. *Journal of the American Society of Nephrology : JASN* **2015**, *26*, 1304-1321.
56. Lindenmeyer, M.T.; Kretzler, M.; Boucherot, A.; Berra, S.; Yasuda, Y.; Henger, A.; Eichinger, F.; Gaiser, S.; Schmid, H.; Rastaldi, M.P. *et al.* Interstitial vascular rarefaction and reduced vegf-a expression in human diabetic nephropathy. *Journal of the American Society of Nephrology : JASN* **2007**, *18*, 1765-1776.
57. Bae, J.; Won, Y.J.; Lee, B.W. Non-albumin proteinuria (nap) as a complementary marker for diabetic kidney disease (dkd). *Life (Basel, Switzerland)* **2021**, *11*.
58. Marcuccilli, M.; Chonchol, M. Nafld and chronic kidney disease. *International journal of molecular sciences* **2016**, *17*, 562.
59. Matthew Morris, E.; Fletcher, J.A.; Thyfault, J.P.; Rector, R.S. The role of angiotensin ii in nonalcoholic steatohepatitis. *Molecular and cellular endocrinology* **2013**, *378*, 29-40.
60. Musso, G.; Cassader, M.; Cohney, S.; Pinach, S.; Saba, F.; Gambino, R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. *Trends in molecular medicine* **2015**, *21*, 645-662.
61. Chawla, T.; Sharma, D.; Singh, A. Role of the renin angiotensin system in diabetic nephropathy. *World journal of diabetes* **2010**, *1*, 141-145.
62. Ma, K.; Gao, W.; Xu, H.; Liang, W.; Ma, G. Role and mechanism of the renin-angiotensin-aldosterone system in the onset and development of cardiorenal syndrome. *Journal of the renin-angiotensin-aldosterone system : JRAAS* **2022**, *2022*, 3239057.
63. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.A.; Boerwinkle, E.; Cohen, J.C.; Hobbs, H.H. Genetic variation in pnpla3 confers susceptibility to nonalcoholic fatty liver disease. *Nature genetics* **2008**, *40*, 1461-1465.
64. Pirazzi, C.; Valenti, L.; Motta, B.M.; Pingitore, P.; Hedfalk, K.; Mancina, R.M.; Burza, M.A.; Indiveri, C.; Ferro, Y.; Montalcini, T. *et al.* Pnpla3 has retinyl-palmitate lipase activity in human hepatic stellate cells. *Human molecular genetics* **2014**, *23*, 4077-4085.
65. Vespasiani-Gentilucci, U.; Gallo, P.; Dell'Unto, C.; Volpentesta, M.; Antonelli-Incalzi, R.; Picardi, A. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. *World journal of gastroenterology* **2018**, *24*, 4835-4845.
66. Targher, G.; Mantovani, A.; Alisi, A.; Mosca, A.; Panera, N.; Byrne, C.D.; Nobili, V. Relationship between pnpla3 rs738409 polymorphism and decreased kidney function in children with nafld. *Hepatology (Baltimore, Md.)* **2019**, *70*, 142-153.
67. Oniki, K.; Saruwatari, J.; Izuka, T.; Kajiwara, A.; Morita, K.; Sakata, M.; Otake, K.; Ogata, Y.; Nakagawa, K. Influence of the pnpla3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. *PloS one* **2015**, *10*, e0132640.
68. Musso, G.; Cassader, M.; Gambino, R. Pnpla3 rs738409 and tm6sf2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. *Hepatology (Baltimore, Md.)* **2015**, *62*, 658-659.
69. Simons, P.; Simons, N.; Stehouwer, C.D.A.; Schalkwijk, C.G.; Schaper, N.C.; Brouwers, M. Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis. *PloS one* **2018**, *13*, e0206174.
70. Wang, T.Y.; Wang, R.F.; Bu, Z.Y.; Targher, G.; Byrne, C.D.; Sun, D.Q.; Zheng, M.H. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. *Nature reviews. Nephrology* **2022**, *18*, 259-268.
71. Tuttle, K.R.; Bakris, G.L.; Bilous, R.W.; Chiang, J.L.; de Boer, I.H.; Goldstein-Fuchs, J.; Hirsch, I.B.; Kalantar-Zadeh, K.; Narva, A.S.; Navaneethan, S.D. *et al.* Diabetic kidney disease: A report from an ada consensus conference. *Diabetes care* **2014**, *37*, 2864-2883.

72. ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Hilliard, M.E.; Isaacs, D.; Johnson, E.L. *et al.* 11. Chronic kidney disease and risk management: Standards of care in diabetes-2023. *Diabetes care* **2023**, *46*, S191-S202.
73. Parving, H.H. Microalbuminuria in essential hypertension and diabetes mellitus. *Journal of hypertension. Supplement : official journal of the International Society of Hypertension* **1996**, *14*, S89-93; discussion S93-84.
74. Satchell, S.C.; Tooke, J.E. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? *Diabetologia* **2008**, *51*, 714-725.
75. Stevens, P.E.; Levin, A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. *Annals of internal medicine* **2013**, *158*, 825-830.
76. Pugliese, G. Updating the natural history of diabetic nephropathy. *Acta diabetologica* **2014**, *51*, 905-915.
77. Wijarnpreecha, K.; Thongprayoon, C.; Boonpheng, B.; Panjawatanan, P.; Sharma, K.; Ungprasert, P.; Pungpapong, S.; Cheungpasitporn, W. Nonalcoholic fatty liver disease and albuminuria: A systematic review and meta-analysis. *European journal of gastroenterology & hepatology* **2018**, *30*, 986-994.
78. Niskanen, L.; Laakso, M. Insulin resistance is related to albuminuria in patients with type ii (non-insulin-dependent) diabetes mellitus. *Metabolism: clinical and experimental* **1993**, *42*, 1541-1545.
79. Fujikawa, R.; Okubo, M.; Egusa, G.; Kohno, N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. *Diabetes research and clinical practice* **2001**, *53*, 99-106.
80. Tervaert, T.W.; Mooyaart, A.L.; Amann, K.; Cohen, A.H.; Cook, H.T.; Drachenberg, C.B.; Ferrario, F.; Fogo, A.B.; Haas, M.; de Heer, E. *et al.* Pathologic classification of diabetic nephropathy. *Journal of the American Society of Nephrology : JASN* **2010**, *21*, 556-563.
81. Gilbert, R.E.; Cooper, M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? *Kidney international* **1999**, *56*, 1627-1637.
82. Gilbert, R.E. Proximal tubulopathy: Prime mover and key therapeutic target in diabetic kidney disease. *Diabetes* **2017**, *66*, 791-800.
83. Retnakaran, R.; Cull, C.A.; Thorne, K.I.; Adler, A.I.; Holman, R.R. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. *Diabetes* **2006**, *55*, 1832-1839.
84. Krolewski, A.S. Progressive renal decline: The new paradigm of diabetic nephropathy in type 1 diabetes. *Diabetes care* **2015**, *38*, 954-962.
85. Yacoub, R.; Campbell, K.N. Inhibition of ras in diabetic nephropathy. *International journal of nephrology and renovascular disease* **2015**, *8*, 29-40.
86. Vallon, V. The proximal tubule in the pathophysiology of the diabetic kidney. *American journal of physiology. Regulatory, integrative and comparative physiology* **2011**, *300*, R1009-1022.
87. Assal, H.S.; Tawfeek, S.; Rasheed, E.A.; El-Lebedy, D.; Thabet, E.H. Serum cystatin c and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. *Clinical medicine insights. Endocrinology and diabetes* **2013**, *6*, 7-13.
88. Mohammadi-Karakani, A.; Asgharzadeh-Haghighi, S.; Ghazi-Khansari, M.; Hosseini, R. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. *Journal of clinical laboratory analysis* **2007**, *21*, 413-417.
89. Huang, Q.; Fei, X.; Zhan, H.; Gong, J.; Zhou, J.; Zhang, Y.; Ye, X.; Song, Y.; Ma, J.; Wu, X. Urinary n-acetyl- β -d-glucosaminidase-creatinine ratio is a valuable predictor for advanced diabetic kidney disease. *Journal of clinical laboratory analysis* **2023**, *37*, e24769.
90. Hong, N.; Lee, M.; Park, S.; Lee, Y.H.; Jin, S.M.; Kim, J.H.; Lee, B.W. Elevated urinary n-acetyl- β -d-glucosaminidase is associated with high glycoalbumin-to-hemoglobin a1c ratio in type 1 diabetes patients with early diabetic kidney disease. *Scientific reports* **2018**, *8*, 6710.

91. Kim, S.R.; Lee, Y.H.; Lee, S.G.; Kang, E.S.; Cha, B.S.; Kim, J.H.; Lee, B.W. Urinary n-acetyl- β -d-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes. *Medicine* **2016**, *95*, e4114.
92. Fiseha, T.; Tamir, Z. Urinary markers of tubular injury in early diabetic nephropathy. *International journal of nephrology* **2016**, *2016*, 4647685.
93. Kim, S.Y.; Jeong, T.D.; Lee, W.; Chun, S.; Sunwoo, S.; Kim, S.B.; Min, W.K. Plasma neutrophil gelatinase-associated lipocalin as a marker of tubular damage in diabetic nephropathy. *Annals of laboratory medicine* **2018**, *38*, 524-529.
94. Hur, M.; Kim, H.; Lee, S.; Cristofano, F.; Magrini, L.; Marino, R.; Gori, C.S.; Bongiovanni, C.; Zanca, B.; Cardelli, P. *et al.* Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, b-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. *BMC infectious diseases* **2014**, *14*, 224.
95. Kim, S.S.; Song, S.H.; Kim, I.J.; Yang, J.Y.; Lee, J.G.; Kwak, I.S.; Kim, Y.K. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. *Diabetes research and clinical practice* **2012**, *97*, 251-257.
96. Lee, J.H.; Yang, F.J.; Tsai, W.Y.; Lee, C.T.; Liu, S.Y.; Yang, W.S.; Tung, Y.C. Serum neutrophil gelatinase-associated lipocalin as a potential biomarker of diabetic kidney disease in patients with childhood-onset type 1 diabetes. *Journal of the Formosan Medical Association = Taiwan yi zhi* **2022**, *121*, 832-840.
97. Kamijo-Ikemori, A.; Sugaya, T.; Kimura, K. Novel urinary biomarkers in early diabetic kidney disease. *Current diabetes reports* **2014**, *14*, 513.
98. Kamijo-Ikemori, A.; Sugaya, T.; Yasuda, T.; Kawata, T.; Ota, A.; Tatsunami, S.; Kaise, R.; Ishimitsu, T.; Tanaka, Y.; Kimura, K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. *Diabetes care* **2011**, *34*, 691-696.
99. Nielsen, S.E.; Sugaya, T.; Hovind, P.; Baba, T.; Parving, H.H.; Rossing, P. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. *Diabetes care* **2010**, *33*, 1320-1324.
100. Panduru, N.M.; Forsblom, C.; Saraheimo, M.; Thorn, L.; Bierhaus, A.; Humpert, P.M.; Groop, P.H. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. *Diabetes care* **2013**, *36*, 2077-2083.
101. Suzuki, K.; Babazono, T.; Murata, H.; Iwamoto, Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. *Diabetes care* **2005**, *28*, 2038-2039.
102. Bonventre, J.V. Kidney injury molecule-1 (kim-1): A urinary biomarker and much more. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* **2009**, *24*, 3265-3268.
103. Han, W.K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J.V. Kidney injury molecule-1 (kim-1): A novel biomarker for human renal proximal tubule injury. *Kidney international* **2002**, *62*, 237-244.
104. Nauta, F.L.; Boertien, W.E.; Bakker, S.J.; van Goor, H.; van Oeveren, W.; de Jong, P.E.; Bilo, H.; Gansevoort, R.T. Glomerular and tubular damage markers are elevated in patients with diabetes. *Diabetes care* **2011**, *34*, 975-981.
105. Cheng, X.; Zhu, J.L.; Li, Y.; Luo, W.W.; Xiang, H.R.; Zhang, Q.Z.; Peng, W.X. Serum biomarkers of isoniazid-induced liver injury: Aminotransferases are insufficient, and opn, l-fabp and hmgb1 can be promising novel biomarkers. *Journal of applied toxicology : JAT* **2022**, *42*, 516-528.
106. Juanola, A.; Graupera, I.; Elia, C.; Piano, S.; Solé, C.; Carol, M.; Pérez-Guash, M.; Bassegoda, O.; Escudé, L.; Rubio, A.B. *et al.* Urinary l-fabp is a promising prognostic biomarker of acif and mortality in patients with decompensated cirrhosis. *Journal of hepatology* **2022**, *76*, 107-114.
107. Ariza, X.; Graupera, I.; Coll, M.; Solà, E.; Barreto, R.; García, E.; Moreira, R.; Elia, C.; Morales-Ruiz, M.; Llopis, M. *et al.* Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. *Journal of hepatology* **2016**, *65*, 57-65.

-
108. Yoshikawa, K.; Iwasa, M.; Eguchi, A.; Kojima, S.; Yoshizawa, N.; Tempaku, M.; Sugimoto, R.; Yamamoto, N.; Sugimoto, K.; Kobayashi, Y. *et al.* Neutrophil gelatinase-associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases. *Hepatology communications* **2017**, *1*, 946-956.